Skip to main content
European Commission logo print header

PET Imaging of Alpha-Synuclein Fibril Formation

Description du projet

L’imagerie TEP dans le diagnostic précoce de la maladie de Parkinson

La maladie de Parkinson (MP) est une affection neurodégénérative dont le diagnostic précoce est compliqué et pour laquelle il n’existe pas de méthodes efficaces de suivi en terme d’évolution et de traitement. Les techniques d’imagerie moléculaire, en particulier la tomographie par émission de positrons (TEP), sont susceptibles d’améliorer le diagnostic de la maladie et l’évaluation de l’efficacité des nouveaux traitements en fonction de la pathologie de chaque patient. Financé par le programme Actions Marie Skłodowska-Curie, le projet PET-AlphaSy met en place un réseau de partenaires universitaires et industriels spécialisés dans les produits radiopharmaceutiques afin de former la prochaine génération de scientifiques dans ce domaine. La recherche et la formation seront axées sur l’apparition de fibrilles d’α-synucléine comme caractéristique de la MP. L’objectif du consortium est de développer et de valider des traceurs TEP pour la visualisation des agrégats pathogènes d’α-synucléine.

Objectif

Too often, physicians have to rely on a trial and error strategy until the most effective treatment for an individual patient is identified. This leads to a critical loss of time, making the healthcare system ineffective and expensive. In respect to drug development, a high failure rate is apparent at all stages of development and ways to reduce this have high priority for the pharmaceutical industry. To this end, drug development and medicinal treatment need to be more personalized and molecular imaging techniques, in particular Positron Emission Tomography (PET) imaging, can be used to achieve this by 1) evaluating the effectiveness of new treatments emerging from the pharmaceutical industry, 2) improving the ability to diagnose diseases, and 3) aid tailoring the treatment based on individual patient pathology. A limiting factor to develop new effective PET imaging probes is the insufficient number of radiopharmaceutical scientists presently available. Our consortium has assembled 6 radiopharmaceutical frontline academic and 10 non-academic partners to address this problem and train the next generation of radiopharmaceutical scientists. Our training will be focused on an unmet scientific need for Parkinson’s Disease (PD). Fibril formation of protein α-synuclein is thought to be the hallmark for PD, but presently, there are no validated PET tracers available for visualization of pathogenic aggregates of this protein. Our scientific goal is to develop such tracer. A successful tracer will have a strong impact on PD-diagnosis and facilitate the development of effective disease modifying treatments. To reach our goals, it is necessary to train our early stage researchers in a highly interdisciplinary fashion spanning from chemistry, over biology, GMP and pharmacy to nuclear medicine. Furthermore, this consortium will train entrepreneurial skills and facilitate start up new enterprises in the current favorable radioisotope market situation.

Coordinateur

KOBENHAVNS UNIVERSITET
Contribution nette de l'UE
€ 892 566,00
Adresse
NORREGADE 10
1165 Kobenhavn
Danemark

Voir sur la carte

Région
Danmark Hovedstaden Byen København
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 892 566,00

Participants (8)

Partenaires (8)